共 50 条
- [1] Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Nelson, Blessie Elizabeth论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USASaleem, Sadia论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USADamodaran, Senthil论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USASomaiah, Neeta论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAPiha-Paul, Sarina Anne论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAMoore, Julia Ann论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAYilmaz, Bulent论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAKarp, Daniel D.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USADumbrava, Ecaterina Elena论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USATsimberidou, Apostolia Maria论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAHong, David S.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAAhnert, Jordi Rodon论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USABooser, Daniel J.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAIbrahim, Nuhad K.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAConley, Anthony Paul论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USABhosale, Priya论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAHernandez, Cristhiam Mauricio Rojas论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USATripathy, Debu论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USANaing, Aung论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USAMeric-Bernstam, Funda论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX USA
- [2] Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancernpj Breast Cancer, 8Melinda L. Telli论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreSara M. Tolaney论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreGeoffrey I. Shapiro论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreMark Middleton论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreSimon R. Lord论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreHendrik Tobias Arkenau论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreAndrew Tutt论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreVandana Abramson论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreEmma Dean论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreTufia C. Haddad论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreRobert Wesolowski论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreJordi Ferrer-Playan论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreThomas Goddemeier论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreThomas Grombacher论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreJennifer Dong论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentrePatricia Fleuranceau-Morel论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreIvan Diaz-Padilla论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research CentreRuth Plummer论文数: 0 引用数: 0 h-index: 0机构: Stanford University School of Medicine,Breast Cancer Now Toby Robins Research Centre
- [3] Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerNPJ BREAST CANCER, 2022, 8 (01)Telli, Melinda L.论文数: 0 引用数: 0 h-index: 0机构: Stanford Univ, Sch Med, Stanford, CA USA Stanford Univ, Sch Med, Stanford, CA USATolaney, Sara M.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA Harvard Med Sch, Boston, MA 02115 USA Stanford Univ, Sch Med, Stanford, CA USAShapiro, Geoffrey, I论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA Harvard Med Sch, Boston, MA 02115 USA Stanford Univ, Sch Med, Stanford, CA USA论文数: 引用数: h-index:机构:Lord, Simon R.论文数: 0 引用数: 0 h-index: 0机构: Univ Oxford, Oxford, England Stanford Univ, Sch Med, Stanford, CA USAArkenau, Hendrik Tobias论文数: 0 引用数: 0 h-index: 0机构: HCA Healthcare, Sarah Cannon Res Inst, London, England UCL, London, England Stanford Univ, Sch Med, Stanford, CA USATutt, Andrew论文数: 0 引用数: 0 h-index: 0机构: Inst Canc Res & Kings Coll, Breast Canc Now Toby Robins Res Ctr, London, England Guys & St Thomas NHS Fdn Trust, London, England Stanford Univ, Sch Med, Stanford, CA USA论文数: 引用数: h-index:机构:Dean, Emma论文数: 0 引用数: 0 h-index: 0机构: Univ Manchester, Manchester, Lancs, England Christie NHS Fdn Trust Manchester, Manchester, Lancs, England AstraZeneca, Oncol R&D, Cambridge, England Alderley Pk, Macclesfield, Cheshire, England Stanford Univ, Sch Med, Stanford, CA USAHaddad, Tufia C.论文数: 0 引用数: 0 h-index: 0机构: Mayo Clin, Rochester, MN USA Stanford Univ, Sch Med, Stanford, CA USAWesolowski, Robert论文数: 0 引用数: 0 h-index: 0机构: Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA Stanford Univ, Sch Med, Stanford, CA USAFerrer-Playan, Jordi论文数: 0 引用数: 0 h-index: 0机构: Ares Trading SA, Eysins, Switzerland Merck KGaA, Darmstadt, Germany Stanford Univ, Sch Med, Stanford, CA USAGoddemeier, Thomas论文数: 0 引用数: 0 h-index: 0机构: Healthcare Business Merck KGaA, Darmstadt, Germany Stanford Univ, Sch Med, Stanford, CA USAGrombacher, Thomas论文数: 0 引用数: 0 h-index: 0机构: Healthcare Business Merck KGaA, Darmstadt, Germany Stanford Univ, Sch Med, Stanford, CA USADong, Jennifer论文数: 0 引用数: 0 h-index: 0机构: EMD Serono, Billerica, MA USA Stanford Univ, Sch Med, Stanford, CA USAFleuranceau-Morel, Patricia论文数: 0 引用数: 0 h-index: 0机构: EMD Serono, Billerica, MA USA Stanford Univ, Sch Med, Stanford, CA USADiaz-Padilla, Ivan论文数: 0 引用数: 0 h-index: 0机构: Ares Trading SA, Eysins, Switzerland Merck KGaA, Darmstadt, Germany GlaxoSmithKline, Zug, Switzerland Stanford Univ, Sch Med, Stanford, CA USA论文数: 引用数: h-index:机构:
- [4] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerCANCER RESEARCH, 2017, 77Tolaney, S.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USASavulsky, C.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAAktan, G.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAXing, D.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAAlmonte, A.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAKarantza, V.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USADiab, S.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA
- [5] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerCANCER RESEARCH, 2018, 78 (04)Tolaney, Sara M.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAKalinsky, Kevin论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAKaklamani, Virginia论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USASavulsky, Claudio论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAOlivo, Martin论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAAktan, Gursel论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAKaufman, Peter A.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAXing, Dongyuan论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAAlmonte, Ana论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAMisir, Soamnauth论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USAKarantza, Vassiliki论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USADiab, Sami论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA
- [6] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176Tolaney, Sara M.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA Dana Farber Canc Inst, Boston, MA 02115 USAKalinsky, Kevin论文数: 0 引用数: 0 h-index: 0机构: Columbia Univ, Med Ctr, New York, NY USA Dana Farber Canc Inst, Boston, MA 02115 USA论文数: 引用数: h-index:机构:Savulsky, Claudio论文数: 0 引用数: 0 h-index: 0机构: Eisai Ltd, Hatfield, Herts, England Dana Farber Canc Inst, Boston, MA 02115 USAOlivo, Martin论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAAktan, Gursel论文数: 0 引用数: 0 h-index: 0机构: Merck Co Inc, Kenilworth, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAKaufman, Peter A.论文数: 0 引用数: 0 h-index: 0机构: Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA Dana Farber Canc Inst, Boston, MA 02115 USAXing, Dongyuan论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAAlmonte, Ana论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAMisir, Soamnauth论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAKarantza, Vassiliki论文数: 0 引用数: 0 h-index: 0机构: Merck Co Inc, Kenilworth, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAYoung, Louise论文数: 0 引用数: 0 h-index: 0机构: Eisai Australia Pty Ltd, Melbourne, Vic, Australia Dana Farber Canc Inst, Boston, MA 02115 USADiab, Sami论文数: 0 引用数: 0 h-index: 0机构: Rocky Mt Canc Ctr, Denver, CO USA Dana Farber Canc Inst, Boston, MA 02115 USA
- [7] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerEUROPEAN JOURNAL OF CANCER, 2017, 72 : S16 - S16Tolaney, S.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Boston, MA 02115 USA Dana Farber Canc Inst, Boston, MA 02115 USASavulsky, C.论文数: 0 引用数: 0 h-index: 0机构: Eisai Ltd, Hatfield, Herts, England Dana Farber Canc Inst, Boston, MA 02115 USAAktan, G.论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAXing, D.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAAlmonte, A.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USAKarantza, V.论文数: 0 引用数: 0 h-index: 0机构: Merck & Co Inc, Kenilworth, NJ USA Dana Farber Canc Inst, Boston, MA 02115 USADiab, S.论文数: 0 引用数: 0 h-index: 0机构: Rocky Mt Canc Ctr, Aurora, CO USA Dana Farber Canc Inst, Boston, MA 02115 USA
- [8] A PHASE 1B MULTI-TUMOR COHORT STUDY OF CABOZANTINIB PLUS ATEZOLIZUMAB IN ADVANCED SOLID TUMORS: RESULTS OF THE TRIPLE-NEGATIVE BREAST CANCER, OVARIAN CANCER, AND ENDOMETRIAL CANCER COHORTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A562 - A562Winer, Ira论文数: 0 引用数: 0 h-index: 0机构: Karmanos Canc Inst, Detroit, MI USA Karmanos Canc Inst, Detroit, MI USAWimalasingham, Akhila论文数: 0 引用数: 0 h-index: 0机构: Queen Mary Univ London, London, England Karmanos Canc Inst, Detroit, MI USA论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Spencer, Kristen论文数: 0 引用数: 0 h-index: 0机构: Rutgers Canc Inst New Jersey, New Brunswick, NJ USA Karmanos Canc Inst, Detroit, MI USABaldini, Capucine论文数: 0 引用数: 0 h-index: 0机构: DITEP, Gustave Roussy, Villejuif, France Karmanos Canc Inst, Detroit, MI USADuska, Linda论文数: 0 引用数: 0 h-index: 0机构: Univ Virginia, Charlottesville, VA USA Karmanos Canc Inst, Detroit, MI USASubbiah, Vivek论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA Karmanos Canc Inst, Detroit, MI USAPatel, Sandip论文数: 0 引用数: 0 h-index: 0机构: Univ Calif San Diego, La Jolla, CA 92093 USA Karmanos Canc Inst, Detroit, MI USAKhrizman, Polina论文数: 0 引用数: 0 h-index: 0机构: MD Anderson Canc Ctr Cooper, Camden, NJ USA Karmanos Canc Inst, Detroit, MI USAVan Lancker, Griet论文数: 0 引用数: 0 h-index: 0机构: Univ Ghent, Ghent, Belgium Karmanos Canc Inst, Detroit, MI USAAndrianova, Lana论文数: 0 引用数: 0 h-index: 0机构: Exelixis Inc, Alameda, CA USA Karmanos Canc Inst, Detroit, MI USAAtwal, Sumandeep论文数: 0 引用数: 0 h-index: 0机构: Exelixis Inc, Alameda, CA USA Karmanos Canc Inst, Detroit, MI USASharma, Keerti论文数: 0 引用数: 0 h-index: 0机构: Exelixis Inc, Alameda, CA USA Karmanos Canc Inst, Detroit, MI USAManso, Luis论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Madrid, Spain Karmanos Canc Inst, Detroit, MI USA
- [9] Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerCLINICAL CANCER RESEARCH, 2022, 28 (08) : 1493 - 1499Batalini, Felipe论文数: 0 引用数: 0 h-index: 0机构: Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA Harvard Med Sch, Dept Med, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAXiong, Niya论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Dept Data Sci, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Eismann, Julia论文数: 0 引用数: 0 h-index: 0机构: Univ Med Ctr Freiburg, Dept Obstet & Gynecol, Freiburg, Germany Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USACantley, Lewis C.论文数: 0 引用数: 0 h-index: 0机构: Cornell Univ, Dept Oncol, Weill Med Coll, New York, NY USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAShapiro, Geoffrey, I论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAAdalsteinsson, Viktor论文数: 0 引用数: 0 h-index: 0机构: Broad Inst MIT & Harvard, Cambridge, MA 02142 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAWiner, Eric P.论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAKonstantinopoulos, Panagiotis A.论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAD'Andrea, Alan论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USASwisher, Elizabeth M.论文数: 0 引用数: 0 h-index: 0机构: Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAMatulonis, Ursula A.论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAWulf, Gerburg M.论文数: 0 引用数: 0 h-index: 0机构: Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA Harvard Med Sch, Dept Med, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USAMayer, Erica L.论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Dept Med, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
- [10] Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerCANCER RESEARCH, 2016, 76Berrak, E.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USAAtkan, G.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USASong, J.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USAAlmonte, A.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USAKarantza, V.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USAYuan, R.论文数: 0 引用数: 0 h-index: 0机构: Eisai Inc, Woodcliff Lake, NJ USA